Biotechnology

Angel Yeast Partners with BakeMark Launching Multiple Product Lines at Bakery China 2024

SHANGHAI, June 4, 2024 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, joined hands with BakeMark to unveil a variety of product lines under the name BakeMark By Angel at Bakery China 2024, the 26th edition of the largest exhibition in...

2024-06-04 19:00 22155

MicroAlgo Inc. (NASDAQ: MLGO) Announced to Jointly Establish a Micro-Consciousness Quantum Research Center With WIMI (NASDAQ: WIMI)

BEIJING, June 4, 2024 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ: MLGO) (the "Company" or "MicroAlgo"), today announced that MicroAlgo and WiMi will jointly establish a micro-consciousness quantum research center. It will integrate physics, mathematics, medicine, genetics, computer science, biology, ...

2024-06-04 16:10 1474

AmpleLogic Launches Advanced aPaaS for Life Sciences with 14 Ready-to-Use Applications

HYDERABAD, India, June 4, 2024 /PRNewswire/ -- AmpleLogic, a leading provider of GAMP solutions, announces the launch of its revolutionaryApplication Platform as a Service (aPaaS) designed specifically for the life sciences sector. This ...

2024-06-04 13:30 1230

GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings

YONGIN, South Korea, June 4, 2024 /PRNewswire/ -- GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals (KASBP) onJune 7-8th at Waltham, Massachusetts as a sponsor to share keynote presentation, present Korean Scientist Awar...

2024-06-04 13:00 1500

Fapon Biopharma Announces a Safer Immunotherapy for Cancers

SAN DIEGO, June 3, 2024 /PRNewswire/ -- At Bio International Convention 2024, which is taking place here inSan Diego during June 3-6, Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, has announced an immunocytokine with modified IL-10M fused to anti-PD-1 ant...

2024-06-04 09:42 1027

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 4, 2024 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center Phase I/II study evaluating RC8...

2024-06-04 09:38 1566

Built by Nature Prize Awards €500,000 to Biobased Construction Innovators

AMSTERDAM, June 4, 2024 /PRNewswire/ -- Built by Nature is pleased to announce the winners of its inaugural global Prize to stimulate uptake of innovative biobased construction materials, with a €250,000 first prize awarded toSingapore-based company Widuz for its bamboo product solutions. Widu...

2024-06-04 08:00 1976

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx

ADELAIDE, South Australia, June 3, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to utilize CelluTx's Recombination Based Plasmid System (RBPS) technology with BioCina's CDMO clients....

2024-06-03 23:37 2405

Datasea Agreement already provided $2.8 million Information Service for its Highly Specialized 5G-AI Communications Platform

Agreement to Have Powerful Revenue Impact and is Expected to Lead to More Lucrative Contracts BEIJING, June 3, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada company engaged in innovative business segments in high-tech intelligent acoustics and 5G-Artifici...

2024-06-03 22:00 3092

Minghui Pharmaceutical Presents Phase 1/2 Clinical Data of MHB088C (B7-H3 ADC) as Monotherapy for the Treatment of Patients with Recurrent or Metastatic Solid Tumors at the 2024 ASCO Annual Meeting

SHANGHAI, June 3, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company, announced today that the preliminary Phase 1/2 clinical data of MHB088C (B7-H3 ADC) was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in an ora...

2024-06-03 21:30 5604

Visionary Pioneering Innovation Across Four Key Frontiers

TORONTO, June 3, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries inCanada and market partners inChina, today announced the Company is pioneeri...

2024-06-03 20:30 2879

Waters Becomes First Liquid Chromatography Column Provider to Receive My Green Lab ACT Ecolabel Certification

News Summary: * Waters becomes the first vendor to obtain ACT™ Ecolabel Certification for 42 of its liquid chromatography columns, providing independent validation of the environmental impact of Waters column manufacturing, use, packaging, and disposal. * Laboratory products that earn the AC...

2024-06-03 20:00 1709

HistoIndex to Showcase Groundbreaking AI-powered Stain-free Digital Pathology Advances with 8 Accepted Abstracts at EASL Congress 2024

* Company to deliver two oral and six poster presentations, including one TOP poster and one selected for poster tour, further reinforcing its leadership position in MASH digital pathology. * HistoIndex's AI-driven solutions provide unprecedented insights into the direct prediction of patient...

2024-06-03 20:00 1973

Formosa Laboratories Completes the Acquisition of Synchem to Expand North American CDMO Footprint

TAOYUAN, June 3, 2024 /PRNewswire/ -- Formosa Laboratories, Inc., a leading API supplier and CDMO headquartered inTaiwan, has successfully completed its acquisition of SynChem, Inc., a contract research laboratory located in suburban Chicago. SynChem will now operate under the new name SynChem-For...

2024-06-03 13:01 1385

MGI Tech's DNBSEQ-E25 and G99 Platforms Set Record for Sequencing Applications on Mount Everest

SHENZHEN, China, June 2, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, recently set a new record for sequencing applications by successfully running sample testing on its cutting-edge DNBSEQ-E25 ...

2024-06-03 11:35 1530

Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting.

NANJING, China, June 2, 2024 /PRNewswire/ -- The annual meeting of the American Society of Clinical Oncology (ASCO) commenced onMay 31st, Showcasing groundbreaking cancer research from around the world. According to official information, over 7,000 abstracts were submitted this year. After rigoro...

2024-06-03 10:57 1829

Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting

* Results from the phase I part of JSKN003-102 was reported at this ASCO Annual Meeting. * JSKN003 exhibited a favorable tolerability and manageable safety profile in heavily pretreated patients with advanced/metastatic solid tumors and demonstrated encouraging antitumor activity during dose ...

2024-06-03 10:17 1752

Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer

SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-06-03 09:35 2770

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) tothe United States (U.S.) Food and Drug Administration (FDA) for its investigational radi...

2024-06-03 09:08 1559

Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2024-06-02 13:19 4036
1 ... 29303132333435 ... 306